More recently, following the randomized phase III clinical trial KATHERINE results, its approval has been expanded to the adjuvant setting to treat patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy5. Here, ERBB2 is linked to breast carcinoma.